The weekly litigation news digest is live. Subscribe now

IP Verse

Actelion Pharmaceuticals US, Inc. v. Apotex Inc. - 1:25-cv-01488

Actelion Pharmaceuticals US, Inc. v. Apotex Inc. (Case No. 1:25-cv-01488), filed on Dec 10, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-01488
Filing Date
Dec 10, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Apotex Inc. -
Actelion Pharmaceuticals US, Inc. -
Nippon Shinyaku Co., Ltd. -

Patents Involved

This case involves 2 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US8791122B2
-US9284280B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Dec 10, 2025Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nippon Shinyaku Co., Ltd. (mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed by Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. (mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,791,122; 9,284,280. (mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/4/2025 (Patentee) and 10/31/2025 (NDA Holder). Date of Expiration of Patent: 6/25/2030 (U.S. Patent No. 9,284,280) and 8/1/2030 (U.S. Patent No. 8,791,122).Thirty Month Stay Deadline: 5/4/2028 (from notice to Patentee) and 4/30/2028 (from notice to NDA holder). (mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025COMPLAINT filed against Apotex Corp. and Apotex Inc. (Filing fee $ 405, receipt number ADEDC-4855997.) - filed by Actelion Pharmaceuticals US, Inc., Actelion Pharmaceuticals Ltd, Nippon Shinyaku Co., Ltd. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(mpb) (Entered: 12/11/2025)PACER Document
Dec 10, 2025No Summons Issued. (mpb)PACER Document